Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Participating in clinical trials isn't just about personal survival—it's about creating a healthier future for loved ones.

This story contains details from testimony referencing suicide and suicidal ideations that are graphic, and some readers may ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Capricor Therapeutics is seeking FDA approval for CAP-1002, targeting heart function in Duchenne Muscular Dystrophy patients.

Results of a randomized, placebo-controlled study demonstrated avatrombopag achieved the primary endpoint of platelet response in heavily pretreated pediatric patients with persistent or chronic ITP.

Every drug, vaccine and diagnostic test we take has to undergo rigorous clinical testing for safety, quality and ...